-
ACLA Opposes Unilateral FDA Action to Regulate Laboratory Developed Tests Under Medical Device Authority
Washington, D.C. – The American Clinical Laboratory Association (ACLA) today issued the following statement after the U.S. Food and Drug Administration (FDA) released a proposed ... Read More -
ACLA Comments to Sen. Cassidy’s White Paper on AI
-
ACLA, Key Stakeholders Urge Medicare Administrative Contractors to Ensure Access to Genetic Testing for Oncology
Washington, D.C. – The American Clinical Laboratory Association (ACLA), along with 44 stakeholders, sent a letter to Medicare Administrative Contractors (MACS), Novitas Solutions Medical Affairs ... Read More -
ACLA Submits Comments on CMS Medicare Physician Fee Schedule Proposed Rule
-
ACLA Response to Draft Local Coverage Determinations, Genetic Testing for Oncology
-
Appendix to ACLA Response to Draft Local Coverage Determinations, Genetic Testing for Oncology
-
Letter from Leading Cancer-Related Provider Groups and Patient Advocates on Genetic Testing for Oncology
-
Understanding the Role of Clinical Laboratories in Supporting Substance Abuse Recovery
September 7, 2023 update: Based on discussions with ACLA and other key stakeholders, CMS has made the decision to withdraw the policy change referenced in the ... Read More -
ACLA Submits Comments on CMS Transitional Coverage For Emerging Technologies Notice
-
ACLA Submits Comments on CMS Pre-Exposure Prophylaxis (PrEP) Proposed NCD